Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or without radiation therapy.
In addition to chemotherapy, adjuvant radiation therapy is considered useful in TNBC, which is used in 67% of patients with TNBC . Some authors consider organ-preserving surgery followed by radiation therapy to be the “gold standard” for the treatment of early breast cancer.
28 Φεβ 2022 · Adriamycin, cyclophosphamide, and paclitaxel combinations are considered to be standard neoadjuvant chemotherapy regimen against TNBC and result in pCR rates of 35–45% . The addition of platinum-based chemotherapy has been proposed.
29 Μαΐ 2020 · The clinical relevancy of the TNBC 7-subtype was further investigated by determining pCR rates after neoadjuvant chemotherapy. Of 146 patients with TNBC, molecular subtype and pCR status were significantly associated ( p = 0.04379) and TNBC subtype was an independent predictor of pCR status ( p = 0.022) by a likelihood ratio test [ 23 ].
9 Νοε 2021 · Tumour heterogeneity and a long-standing paucity of effective therapies other than chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype with the least...
29 Μαΐ 2024 · The treatment landscape for early-stage TNBC has changed considerably in the last decade, with new additions to neoadjuvant therapy (NAT) aimed at improving pathologic responses and outcomes. In this study, we assess real world data regarding treatment and outcomes in those with early-stage TNBC.
14 Αυγ 2024 · The Neo-Real study (GBECAM-0123) is a real-world data effort evaluating patients with TNBC treated with neoadjuvant P + CT in ten cancer centers since July 2020. The objective of this analysis...
